ArticleDeutsches Arzteblatt international2014
Patients with cancer of unknown primary: a retrospective analysis of 223 patients with adenocarcinoma or undifferentiated carcinoma.
Article in Deutsches Arzteblatt international, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed.
- Mortality Trends in Cancer of Unknown Primary Site in Serbia, 1990-2024: A Joinpoint Regression and Age-Period-Cohort Analysis.Epidemiologia (Basel, Switzerland) · 2026Article
- Article
- Cancer Diaspora of Undifferentiated Cancer.Cureus · 2024Article
- Article
- Article
- A generational comparison for unfavorable cancer of unknown primary in a single institute over 20 years.Cancer medicine · 2023Article
- Management and prognosis of patients with cancer of unknown primary: 20 years of experience.Turkish journal of medical sciences · 2023Article
- Real-world data analysis of patients with cancer of unknown primary.Scientific reports · 2021Article
- Rare primary peritoneal mucinous adenocarcinoma in a 69-year-old man.Clinical case reports · 2021Article
- [Case report of an osseous (and lymphogenic) thymic carcinoma in an adult].Der Orthopade · 2021Article
- [CUP in the liver].Der Pathologe · 2020Review
- Review
- Does Cancer of Unknown Primary (CUP) Truly Exist as a Distinct Cancer Entity?Frontiers in oncology · 2019Review
- Survival outcome differences based on treatments used and knowledge of the primary tumour site for patients with cancer of unknown and known primary in Ontario.Current oncology (Toronto, Ont.) · 2018Article
- CUP Syndrome-Metastatic Malignancy with Unknown Primary Tumor.Deutsches Arzteblatt international · 2018Review
- Molecular driver alterations and their clinical relevance in cancer of unknown primary site.Oncotarget · 2016Article
- A Simple Risk Model to Predict Survival in Patients With Carcinoma of Unknown Primary Origin.Medicine · 2015Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundCancer of unknown primary (CUP) now accounts for 2-3% of all fatal cases of cancer in Germany. Histologically, most of these tumors are either adenocarcinoma or undifferentiated carcinoma. Scant data on their clinical features and prognosis are now available, and the published survival times are highly variable. In this article, we document and analyze our own experience with CUP to date.
methodWe took all 223 patients with CUP (adenocarcinoma or undifferentiated carcinoma) whom we saw in our CUP clinic from 2006 to 2010 as an unaltered sample for retrospective analysis of clinical data and overall survival. We performed the analysis with Kaplan-Meier plotting, log-rank testing, and Cox regression.
resultsWith a median follow-up time of 32.9 months, the median survival from the time of diagnosis was 16.5 months. Metastases were most commonly found in the lymph nodes, followed by the liver, bones, and lungs. The main pre-treatment prognostic variables that remained significant after adjustment for multiple testing were the Eastern Cooperative Oncology Group (ECOG) score for overall state of health and the number of organ systems involved. These variables were used to construct a practice-oriented risk stratification.
conclusionIn patients with adeno- or undifferentiated CUP syndrome, the ECOG score and the number of organ systems involved are important risk factors.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.